Latest news with #TVRD
Yahoo
4 days ago
- Business
- Yahoo
Tvardi: Q2 Earnings Snapshot
SUGAR LAND, Texas (AP) — SUGAR LAND, Texas (AP) — Tvardi Therapeutics, Inc. (TVRD) on Thursday reported second-quarter net income of $4.2 million. On a per-share basis, the Sugar Land, Texas-based company said it had net loss of $1. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on TVRD at Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
San Francisco Chronicle
4 days ago
- Business
- San Francisco Chronicle
Tvardi: Q2 Earnings Snapshot
SUGAR LAND, Texas (AP) — SUGAR LAND, Texas (AP) — Tvardi Therapeutics, Inc. (TVRD) on Thursday reported second-quarter net income of $4.2 million. On a per-share basis, the Sugar Land, Texas-based company said it had net loss of $1. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 51 cents per share. _____
Business Insider
31-05-2025
- Business
- Business Insider
Tvardi Therapeutics files to sell 2.08M shares of common stock for holders
16:05 EDT Tvardi Therapeutics (TVRD) files to sell 2.08M shares of common stock for holders Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Yahoo
13-05-2025
- Business
- Yahoo
Tvardi: Q1 Earnings Snapshot
STAMFORD, Conn. (AP) — STAMFORD, Conn. (AP) — Tvardi Therapeutics, Inc. (TVRD) on Tuesday reported a loss of $4.9 million in its first quarter. On a per-share basis, the Stamford, Connecticut-based company said it had a loss of $3.22. The biotechnology company posted revenue of $2.6 million in the period. _____ This story was generated by Automated Insights ( using data from Zacks Investment Research. Access a Zacks stock report on TVRD at Sign in to access your portfolio
